Report      Database

    United States Off-Label Drugs Market & Forecast

    Date: 13 Apr, 2015              Type: Life Science              Pages: 67

    United States Off-Label Drugs Market & Forecast
    • Electronic Access - Single User License
      $1,200.00
    • CD-ROM Mail Delivery
      $1,300.00
    • Hard-copy Mail Delivery
      $1,300.00
    • Electronic Access - Multi User License
      $1,800.00

    Off–label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved Drugs for any use consistent with available scientific data and proper medical practice, but unfortunately, this is done without adequate scientific data. Often, when the best available therapeutic option fails, patients demand new approach or new treatment which ultimately leads to off–label uses. 

    Off–label use is very common in United States. United States Off–label Drugs demand has grown at a fast pace in the past decade and likely to grow in the forecasting period. It is likely that United States off–label market will cross the figure of 60 Billion by the year 2020. Central Nervous System (CNS) and Cancer off–label Drugs controls the largest market share of the total US off–label Drugs market. Anti–Infectives Off–Label Drugs Market and Anti–Ashmatics Off–Label Drugs together are expected to control close to 35% market share by 2020.  

    Renub Research study titled “United States Off–Label Drugs Market & Forecast” report provides a comprehensive analysis of the emerging Off–Label Drugs market. The report also entails commonly prescribed Off–Label Drugs, Perspective of Physicians, Patients, Pharmaceutical Companies and Regulatory Authorities, Off–label Promotion Settlements under the False Claims Act. The report also studies Drivers and Challenges of United States Off–Label Drugs market. This 67 page report with 16 Figures and 1 Table studies 6 Off–Label Drugs Segment.

    The 6 Off–Label Drugs Segment Covered in the Report are as Follows:

    1. Cancer Off–Label Drugs
    2. Central Nervous System (CNS) Off–Label Drugs
    3. Anti–Ashmatics Off–Label Drugs 
    4. Anti–Allergies Off–Label Drugs 
    5. Anti–Hypertensives Off–Label Drugs
    6. Anti–Infectives Off–Label Drugs

    Data Sources 

    This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts. 

    Primary sources include industry surveys and telephonic interviews with industry experts. 

    Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 

    1. Executive Summary

    2. United States Off–Label Drugs Market & Forecast

    3. United States Off–Label Drugs Market Share & Forecast

    4. United States Off–Label Drugs Market – Segment wise

    4.1 United States – Cancer Off–Label Drugs Market & Forecast
    4.2 United States – Central Nervous System (CNS) Off–Label Drugs Market & Forecast
    4.3 United States – Anti–Ashmatics Off–Label Drugs Market & Forecast
    4.4 United States – Anti–Allergies Off–Label Drugs Market & Forecast
    4.5 United States – Anti–Hypertensives Off–Label Drugs Market & Forecast
    4.6 United States – Anti–Infectives Off–Label Drugs Market & Forecast

    5. Drugs Commonly Prescribed Off–Label

    6. Off–Label Use of Medicine & Different Perspectives

    6.1 Physicians Perspective
    6.1.1 Physicians’ Liability for Off–Label Prescriptions
    6.2 Patients Perspective
    6.3 Perspective of the Pharmaceutical Companies
    6.4 Perspective of Regulatory Agencies

    7. Off–Label Promotion Settlements Under The False Claims Act

    7.1 Year 2004
    7.2 Year 2005
    7.3 Year 2006
    7.4 Year 2007
    7.5 Year 2008
    7.6 Year 2009
    7.7 Year 2010
    7.8 Year 2011
    7.9 Year 2012
    7.10 Year 2013
    7.11 Year 2014

    8. United States Off–Label Drugs Market – Growth Drivers

    8.1 Clinical Practices and Application in the Off–Label Drugs
    8.2 Vulnerable Patient Populations: Information and Access
    8.3 Off–Label Promotion Reform

    9. United States Off–Label Drugs Market – Challenges

    9.1 Lack of Regulation & Information of the United States Off–Label Drugs Market
    9.2 Reimbursement
    9.3 Safety and Efficacy of Unapproved and Under Evaluated Use
    9.4 Point of View on Bioethical Off–Label Drugs Use
    9.5 Inaccuracy of Off–Label Clinical Publications 

    List of Figures:

    Figure 2–1: United States – Off–Label Drugs Market (Billion US$), 2011 – 2014
    Figure 2–2: United States – Forecast for Off–Label Drugs Market (Billion US$), 2015 – 2020

    Figure 3–1: United States – Off–Label Drugs Market Share (Percent), 2011 – 2014
    Figure 3–2: United States – Forecast for Off–Label Drugs Market Share (Percent), 2015 – 2020

    Figure 4–1: United States – Cancer Off–Label Drugs Market (Billion US$), 2008 – 2014
    Figure 4–2: United States – Forecast for Cancer Off–Label Drugs Market (Billion US$), 2015 – 2020
    Figure 4–3: United States – Central Nervous System (CNS) Off–Label Drugs Market (Billion US$), 2009 – 2014
    Figure 4–4: United States – Forecast for Central Nervous System (CNS) Off–Label Drugs Market (Billion US$), 2015 – 2020
    Figure 4–5: United States – Anti–Ashmatics Off–Label Drugs Market (Billion US$), 2010 – 2014
    Figure 4–6: United States – Forecast for Anti–Ashmatics Off–Label Drugs Market (Billion US$), 2015 – 2020
    Figure 4–7: United States – Anti–Allergies Off–Label Drugs Market (Billion US$), 2011 – 2014
    Figure 4–8: United States – Forecast for Anti–Allergies Off–Label Drugs Market (Billion US$), 2015 – 2020
    Figure 4–9: United States – Anti–Hypertensives Off–Label Drugs Market (Billion US$), 2009 – 2014
    Figure 4–10: United States – Forecast for Anti–Hypertensives Off–Label Drugs Market (Billion US$), 2015 – 2020
    Figure 4–11: United States – Anti–Infectives Off–Label Drugs Market (Billion US$), 2008 – 2014
    Figure 4–12: United States – Forecast for Anti–Infectives Off–Label Drugs Market (Billion US$), 2015 – 2020

    List of Tables: 

    Table 5–1: Commonly Prescribed Off–Label Drugs

    • Description
      Price
    • Chapter 1, 2 & 3     Pages : 8
      $700
    • Chapter 4     Pages : 13
      $600
    • Chapter 5     Pages : 2
      $100
    • Chapter 6     Pages : 0
      $150
    • Chapter 7     Pages : 12
      $200
    • Chapter 8 & 9     Pages : 9
      $200

    Related Products

    • United States Anesthesia Drugs Market & Forecast


      United States Anesthesia Drugs Market & Forecast
      United States Anesthesia Market is expected to be more than US$ 4 Billion by 2022. This growth is driven by increasing incidence of cardiovascular cases, growing old age population and rising number of urgent surgeries in United States. Private as well as public health insurers also help to boost th...
      Date: 12 Jun, 2017
      Type: Life Science
      Pages: 127
      Price: $1,800.00
    • Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis


      Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis
      Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The curren...
      Date: 02 Dec, 2013
      Type: Life Science
      Pages: 110
      Price: $1,475.00